Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Young woman with mild bone marrow dysplasia, GATA2 and ASXL1 mutation treated with allogeneic hematopoietic stem cell transplantation.
Lübking A, Vosberg S, Konstandin NP, Dufour A, Graf A, Krebs S, Blum H, Weber A, Lenhoff S, Ehinger M, Spiekermann K, Greif PA, Cammenga J. Lübking A, et al. Among authors: ehinger m. Leuk Res Rep. 2015 Oct 17;4(2):72-5. doi: 10.1016/j.lrr.2015.10.001. eCollection 2015. Leuk Res Rep. 2015. PMID: 26716079 Free PMC article.
SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function.
Hansen N, Ågerstam H, Wahlestedt M, Landberg N, Askmyr M, Ehinger M, Rissler M, Lilljebjörn H, Johnels P, Ishiko J, Melo JV, Alexander WS, Bryder D, Järås M, Fioretos T. Hansen N, et al. Among authors: ehinger m. Leukemia. 2013 Jan;27(1):130-5. doi: 10.1038/leu.2012.169. Epub 2012 Jun 22. Leukemia. 2013. PMID: 22824785 Free PMC article.
Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML.
Delsing Malmberg E, Johansson Alm S, Nicklasson M, Lazarevic V, Ståhlman S, Samuelsson T, Lenhoff S, Asp J, Ehinger M, Palmqvist L, Brune M, Fogelstrand L. Delsing Malmberg E, et al. Among authors: ehinger m. Leuk Lymphoma. 2019 Feb;60(2):409-417. doi: 10.1080/10428194.2018.1485910. Epub 2018 Aug 2. Leuk Lymphoma. 2019. PMID: 30068244 Free article.
Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study.
Rosso A, Juliusson G, Lorenz F, Lehmann S, Derolf Å, Deneberg S, Jädersten M, Antunovic P, Cammenga J, Möllgård L, Wennström L, Ölander E, Ehinger M, Fogelstrand L, Höglund M, Lazarevic VL. Rosso A, et al. Among authors: ehinger m. Leuk Lymphoma. 2021 Aug;62(8):1973-1981. doi: 10.1080/10428194.2021.1889539. Epub 2021 Mar 10. Leuk Lymphoma. 2021. PMID: 33719843 Free article.
Combined GLUT1 and OXPHOS inhibition eliminates acute myeloid leukemia cells by restraining their metabolic plasticity.
Rodriguez-Zabala M, Ramakrishnan R, Reinbach K, Ghosh S, Oburoglu L, Falqués-Costa A, Bellamkonda K, Ehinger M, Peña-Martínez P, Puente-Moncada N, Lilljebjörn H, Cammenga J, Pronk CJ, Lazarevic V, Fioretos T, Hagström-Andersson AK, Woods NB, Järås M. Rodriguez-Zabala M, et al. Among authors: ehinger m. Blood Adv. 2023 Sep 26;7(18):5382-5395. doi: 10.1182/bloodadvances.2023009967. Blood Adv. 2023. PMID: 37505194 Free PMC article.
CXCR4 Signaling Has a CXCL12-Independent Essential Role in Murine MLL-AF9-Driven Acute Myeloid Leukemia.
Ramakrishnan R, Peña-Martínez P, Agarwal P, Rodriguez-Zabala M, Chapellier M, Högberg C, Eriksson M, Yudovich D, Shah M, Ehinger M, Nilsson B, Larsson J, Hagström-Andersson A, Ebert BL, Bhatia R, Järås M. Ramakrishnan R, et al. Among authors: ehinger m. Cell Rep. 2020 May 26;31(8):107684. doi: 10.1016/j.celrep.2020.107684. Cell Rep. 2020. PMID: 32460032 Free PMC article.
101 results